Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Solriamfetol - Jazz Pharmaceuticals/SK Biopharmaceuticals

Drug Profile

Solriamfetol - Jazz Pharmaceuticals/SK Biopharmaceuticals

Alternative Names: ADX-N05; ARL-N05; JZP-110; SKL-N05

Latest Information Update: 12 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SK Holdings
  • Developer Jazz Pharmaceuticals plc; SK biopharmaceuticals
  • Class Carbamates; Sleep disorder therapies; Urologics
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Narcolepsy; Sleep apnoea syndrome
  • Phase II Hypersomnia
  • Phase I Renal failure
  • No development reported Depressive disorders

Most Recent Events

  • 21 Dec 2018 FDA assigns PDUFA action date of 20/03/2019 for solriamfetol for Narcolepsy and Sleep apnoea syndrome
  • 09 Nov 2018 Preregistration for Narcolepsy in European Union (PO)
  • 09 Nov 2018 Preregistration for Sleep apnoea syndrome in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top